<hvuh class="hsuyua"></hvuh>

公海555000官网

Be the most trusted biotech company

2024-06-21

IMF Chief Economist Visits Henlius: Witnessing China's Economic Vitality and Biopharmaceutical Innovation
2024-06-19

Results from the Preclinical Study of HLX99, an Innovative Neurodegenerative Diseases Therapeutic of Henlius Released at ENCALS Meeting 2024
2024-06-18

Henlius to Make Its Debut at the World ADC Asia 2024
2024-06-17

Advances in Immunotherapy for mCRC: Serplulimab Combo Published in MED
2024-06-12

Henlius Shines at 2024 BIO International Convention, Showcasing Its Innovative Strength and Global Achievements
2024-06-07

Henlius Expands Collaboration with Sermonix for Lasofoxifene in All of Asia
2024-06-06

Henlius Trastuzumab Begins its Journey to Saudi Arabia
2024-06-04

Latest Results of Serplulimab Released at 2024 ASCO
2024-05-27

Henlius Rituximab Receives Marketing Approval in Peru